Sanofi-Synthelabo’s Eloxatin for Postsurgical Treatment of Stage III Colon Cancer
November 5, 2004 by admin · Leave a Comment
On November 5, 2004 Sanofi-Synthelabo’s Eloxatin™ (oxaliplatin for injection) received US FDA approval for use in combination with conventional chemotherapy (5-flurouracil and leukovorin) for the postsurgical treatment of stage III colon cancer patients. According to the company, this is the first new chemotherapy approval for the adjuvant treatment of colon cancer in over a decade. [...]
Lorus Therapeutics GTI-2040 for Colon Cancer
May 4, 2004 by admin · Leave a Comment
On May 4, 2004 Lorus Therapeutics Inc. reported that it had initiated a clinical trial of GTI-2040 involving patients with advanced unresectable colon cancer. GTI-2040 was administered in combination with FDA approved chemotherapies capecitabine and oxaliplatin. Capectiabine is a first-line therapy while oxaliplatin is approved for use with 5 fluorouracil/ Leucovorin. This study is one [...]